Tiny Lungs, Big Differences: Navigating the Varied COVID-19 Landscape in Neonates vs. Infants via Biomarkers and Lung Ultrasound.

Publication date: Feb 13, 2024

Due to their susceptibilities, neonates and infants face unique SARS-CoV-2 challenges. This retrospective study will compare the illness course, symptoms, biomarkers, and lung damage in neonates and infants with SARS-CoV-2 infection from February 2020 to October 2023. This study was conducted at two hospitals in Timisoara, Romania, using real-time multiplex PCR to diagnose and lung ultrasonography (LUS) to assess lung involvement. Neonates had a more severe clinical presentation, an increased immune response, and greater lung involvement. Neonates had more PCR-positive tests (p = 0. 0089) and longer hospital stays (p = 0. 0002). In neonates, LDH, CRP, and ferritin levels were higher, indicating a stronger inflammatory response. Reduced oxygen saturation in neonates indicates respiratory dysfunction. The symptoms were varied. Infants had fever, cough, and rhinorrhea, while neonates had psychomotor agitation, acute dehydration syndrome, and candidiasis. This study emphasizes individualized care and close monitoring for neonatal SARS-CoV-2 infections. Newborn lung ultrasonography showed different variances and severity levels, emphasizing the need for targeted surveillance and therapy. Newborns have high lung ultrasound scores (LUSS), indicating significant lung involvement. Both groups had initial lung involvement, but understanding these modest differences is crucial to improving care for these vulnerable populations.

Open Access PDF

Concepts Keywords
Biomedicines biomarkers
February COVID-19
Rhinorrhea infants
Tiny inflammatory markers
Ultrasound lung disease
lung ultrasound
multisystem inflammatory syndrome


Type Source Name
disease MESH COVID-19
pathway REACTOME SARS-CoV-2 Infection
disease VO time
disease IDO immune response
drug DRUGBANK Oxygen
disease MESH dehydration
disease MESH syndrome
disease MESH candidiasis
disease MESH Respiratory Diseases
disease MESH infections
disease MESH lung disease
disease VO population
disease IDO susceptibility
drug DRUGBANK Coenzyme M
disease MESH pneumonia
disease VO effectiveness
disease MESH Emergency
disease MESH Infectious Diseases
disease IDO process
disease MESH bacterial infection
disease MESH superinfection
disease IDO immunodeficiency
disease MESH cystic fibrosis
disease VO frequency
disease MESH apathy
disease IDO symptom
drug DRUGBANK Pentaerythritol tetranitrate
disease MESH abnormalities
drug DRUGBANK Medical air
drug DRUGBANK Water
disease IDO infection
disease MESH nosocomial infection

Original Article

(Visited 1 times, 1 visits today)